Is DarioHealth going out of business?

DarioHealth Corp. (DRIO) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

DarioHealth Corp. (DRIO) scores 13 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: FCF margin: -211.04%

Five questions, kept separate

Survival - Critical

3-5 mo of estimated runway from 2026-06-30, based on $14.0M of cash and short-term investments against $44.3M of annual burn. Debt pressure is the other decisive risk.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Extreme expectations

-27.2% net-cash backing support an extreme expectations pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• FCF margin: -211.04%
• Debt / Equity: 0.59x
• ROIC: -43.10%
• Interest coverage: -6.9x
• Filing event risk: Going-Concern Warning (-8 pts)
• Cash Runway (years): 0.32y
• Revenue CAGR (3Y): -6.84%
• EPS CAGR (3Y): 58.53%
• R&D intensity: 37.21%
• Revenue growth YoY: -3.58% (YoY)
• Return on Assets: -36.93%
• Debt Maturity Runway: 100% long-term (Long-term focused)

Read from filings through 2026-09-04.

Price as of 2026-09-07.